Iatrogenic disorders from cancer treatment.
All cancer therapies have potential and often serious side effects. With judicious selection of therapies, the risks are acceptable as are the contributions to better care, including that of iatrogenic disorders from therapy. It should, again, be stressed that new drugs and new modalities in combinations of treatments increase iatrogenic disorders from cancer therapy; as this increase is more and more appreciated, adjustments in schedules are resulting in decreased incidences of such disorders. Truly long-term effects over decades or generations are, of course, not yet known for most of the modern cancer therapies.
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D001853:Bone Marrow / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000209:etiology; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D005767:Gastrointestinal Diseases / Q000209:etiology; D006801:Humans; D007165:Immunosuppression Therapy; D007674:Kidney Diseases / Q000209:etiology; D008660:Metabolism / Q000187:drug effects; D009369:Neoplasms / Q000209:etiology / Q000628:therapy*; D009422:Nervous System Diseases / Q000209:etiology; D011014:Pneumonia / Q000209:etiology; D011658:Pulmonary Fibrosis / Q000209:etiology; D011878:Radiotherapy / Q000009:adverse effects
D000970:Antineoplastic Agents